Mikail D. Levasseur

Mikail D. Levasseur

Auto-generated profile, based on publicly available information

Mikail D. Levasseur

Laboratory of Organic Chemistry, ETH Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Chemical Reviews
Verified
Journal Article
Closed access
TEThomas G. W. Edwardson
Thomas G. W. Edwardson
MLMikail D. Levasseur
Mikail D. Levasseur
STStephan Tetter
Stephan Tetter
ASAngela Steinauer
Angela Steinauer
MHMao Hori
Mao Hori
DHDonald Hilvert
Donald Hilvert

5 October 2016 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
MPMartina Pigoni
Martina Pigoni
JWJohanna Wanngren
Johanna Wanngren
PKPeer-Hendrik Kuhn
Peer-Hendrik Kuhn
KMKathryn M. Munro
Kathryn M. Munro
JGJenny M. Gunnersen
Jenny M. Gunnersen
SLStefan F. Lichtenthaler
Stefan F. Lichtenthaler
The protease BACE1 (beta-site APP cleaving enzyme) is a major drug target in Alzheimer’s disease. However, BACE1 therapeutic inhibition may cause unwanted adverse effects due to its additional functions in the nervous system, such as in myelination and neuronal connectivity. Additionally, recent proteomic studies investigating BACE1 inhibition in cell lines and cultured murine neurons identified a wider range of neuronal membrane proteins as potential BACE1 substrates, including seizure protein 6 (SEZ6) and its homolog SEZ6L. We generated antibodies against SEZ6 and SEZ6L and validated these proteins as BACE1 substrates in vitro and in vivo. Levels of the soluble, BACE1-cleaved ectodomain of both proteins (sSEZ6, sSEZ6L) were strongly reduced upon BACE1 inhibition in primary neurons and also in vivo in brains of BACE1-deficient mice. BACE1 inhibition increased neuronal surface levels of SEZ6 and SEZ6L as shown by cell surface biotinylation, demonstrating that BACE1 controls surface expression of both proteins. Moreover, mass spectrometric analysis revealed that the BACE1 cleavage site in SEZ6 is located in close proximity to the membrane, similar to the corresponding cleavage site in SEZ6L. Finally, an improved method was developed for the proteomic analysis of murine cerebrospinal fluid (CSF) and was applied to CSF from BACE-deficient mice. Hereby, SEZ6 and SEZ6L were validated as BACE1 substrates in vivo by strongly reduced levels in the CSF of BACE1-deficient mice. This study demonstrates that SEZ6 and SEZ6L are physiological BACE1 substrates in the murine brain and suggests that sSEZ6 and sSEZ6L levels in CSF are suitable markers to monitor BACE1 inhibition in mice.

24 July 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
Pietro RoversiPietro Roversi
Pietro Roversi
LMLucia Marti
Lucia Marti
ACAlessandro T. Caputo
Alessandro T. Caputo
DADominic S. Alonzi
Dominic S. Alonzi
JHJohan C. Hill
Johan C. Hill
NZNicole Zitzmann
Nicole Zitzmann
Significance: A dedicated endoplasmic reticulum quality control (ERQC) machinery ensures the correct fold of secreted proteins bearing N-linked glycans, which constitute around a fifth of the whole proteome and are essential for many important cellular processes such as signaling, immunity, adhesion, transport, and metabolism. UDP-glucose:glycoprotein glucosyltransferase (UGGT) is the sole checkpoint enzyme of ERQC, flagging incorrectly folded glycoproteins for ER retention. Here, we describe crystal structures of full-length UGGT. We show that enzymatic activity depends on interdomain conformational mobility, indicating that the intrinsic flexibility of UGGT may endow the enzyme with the promiscuity needed to recognize and reglucosylate its many different substrates.

27 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
HTHanne L. P. Tytgat
Hanne L. P. Tytgat
CLChia-Wei Lin
Chia-Wei Lin
MLMikail D. Levasseur
Mikail D. Levasseur
MTMarkus B Tomek
Markus B Tomek
CRChristoph Rutschmann
Christoph Rutschmann
TKTimothy G. Keys
Timothy G. Keys
Glycosylation of proteins profoundly impacts their physical and biological properties. Yet our ability to engineer novel glycoprotein structures remains limited. Established bacterial glycoengineering platforms require secretion of the acceptor protein to the periplasmic space and preassembly of the oligosaccharide substrate as a lipid-linked precursor, limiting access to protein and glycan substrates respectively. Here, we circumvent these bottlenecks by developing a facile glycoengineering platform that operates in the bacterial cytoplasm. The Glycoli platform leverages a recently discovered site-specific polypeptide glycosyltransferase together with variable glycosyltransferase modules to synthesize defined glycans, of bacterial or mammalian origin, directly onto recombinant proteins in the E. coli cytoplasm. We exploit the cytoplasmic localization of this glycoengineering platform to generate a variety of multivalent glycostructures, including self-assembling nanomaterials bearing hundreds of copies of the glycan epitope. This work establishes cytoplasmic glycoengineering as a powerful platform for producing glycoprotein structures with diverse future biomedical applications.

2 September 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TDThomas Denèfle
Thomas Denèfle
HBHéloise Boullet
Héloise Boullet
LHLinda Herbi
Linda Herbi
CNClara Newton
Clara Newton
AMAna Carolina Martinez-Torres
Ana Carolina Martinez-Torres
PKPhilippe Karoyan
Philippe Karoyan

21 April 2021 in ACS Chemical Biology
Verified
Journal Article
Closed access
MLMikail D. Levasseur
Mikail D. Levasseur
SMShiksha Mantri
Shiksha Mantri
THTakahiro Hayashi
Takahiro Hayashi
MRMaria Reichenbach
Maria Reichenbach
SHSvenja Hehn
Svenja Hehn
DHDonald Hilvert
Donald Hilvert